Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib,...
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced...
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter of 2023 LAS VEGAS, NV...
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agencyPAX-101 internally developed supply chain entering final stagesTARRYTOWN, NY, June 14, 2023...
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical industry, is excited to announce...
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent...
Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We”...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial...
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024ENCINITAS, Calif., June 14, 2023 (GLOBE...
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a...
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and...
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at...
Teaming up with Mark Cuban Cost Plus Drug Company, SmithRx will start offering members access beginning in July 2023SAN FRANCISCO,...